Zacks Investment Research upgraded shares of INDIVIOR PLC/S (OTCMKTS:INVVY) from a sell rating to a buy rating in a report issued on Thursday morning, Zacks.com reports. Zacks Investment Research currently has $13.00 target price on the stock.
According to Zacks, “Indivior PLC operates as a specialty pharmaceutical company. It is engaged in discovering and developing medications and treatment for alcohol addiction, opioid overdose, cocaine intoxication and co-occurring conditions, such as schizophrenia. The Company markets and promotes SUBOXONE (buprenorphine and naloxone) Sublingual Film, SUBOXONE (buprenorphine and naloxone) Sublingual Tablet, and SUBUTEX (buprenorphine) Sublingual Tablet, each buprenorphine-based treatment for opioid. Indivior PLC is based in United States. “
Several other research firms have also issued reports on INVVY. Stifel Nicolaus upgraded shares of INDIVIOR PLC/S from a hold rating to a buy rating in a report on Monday, July 27th. Citigroup upgraded shares of INDIVIOR PLC/S from a neutral rating to a buy rating in a report on Monday, July 27th. Jefferies Financial Group upgraded shares of INDIVIOR PLC/S from a hold rating to a buy rating in a research note on Monday, July 27th. Finally, ValuEngine upgraded shares of INDIVIOR PLC/S from a sell rating to a hold rating in a research note on Tuesday, May 19th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus price target of $13.00.
INDIVIOR PLC/S stock opened at $11.05 on Thursday. The company has a debt-to-equity ratio of 7.05, a quick ratio of 1.63 and a current ratio of 1.75. INDIVIOR PLC/S has a 52-week low of $2.23 and a 52-week high of $40.00. The firm has a 50 day moving average price of $10.97 and a two-hundred day moving average price of $5.31. The firm has a market cap of $1.62 billion, a price-to-earnings ratio of -15.78 and a beta of 0.38.
INDIVIOR PLC/S Company Profile
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The company's product pipeline focuses on treating opioid use disorder, alcohol use disorder, opiate overdose, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex.
Featured Story: Trading Options- What is a Strangle?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for INDIVIOR PLC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INDIVIOR PLC/S and related companies with MarketBeat.com's FREE daily email newsletter.